603566 Stock Overview
Engages in the research and development, production, and marketing of veterinary biological products and drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pulike Biological Engineering, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.36 |
| 52 Week High | CN¥25.00 |
| 52 Week Low | CN¥10.80 |
| Beta | 0.33 |
| 1 Month Change | -0.48% |
| 3 Month Change | -2.14% |
| 1 Year Change | -13.63% |
| 3 Year Change | -48.28% |
| 5 Year Change | -25.99% |
| Change since IPO | 10.60% |
Recent News & Updates
Recent updates
Investors Still Waiting For A Pull Back In Pulike Biological Engineering, Inc. (SHSE:603566)
Jan 03
Pulike Biological Engineering's (SHSE:603566) Weak Earnings May Only Reveal A Part Of The Whole Picture
Sep 04Pulike Biological Engineering, Inc. (SHSE:603566) Looks Just Right With A 34% Price Jump
May 21Need To Know: The Consensus Just Cut Its Pulike Biological Engineering, Inc. (SHSE:603566) Estimates For 2024
Apr 28Why Investors Shouldn't Be Surprised By Pulike Biological Engineering, Inc.'s (SHSE:603566) Low P/E
Mar 21Pulike Biological Engineering (SHSE:603566) Seems To Use Debt Quite Sensibly
Feb 28Shareholder Returns
| 603566 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.5% | 0.2% | -0.9% |
| 1Y | -13.6% | 12.8% | 22.0% |
Return vs Industry: 603566 underperformed the CN Pharmaceuticals industry which returned 12.8% over the past year.
Return vs Market: 603566 underperformed the CN Market which returned 22% over the past year.
Price Volatility
| 603566 volatility | |
|---|---|
| 603566 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 603566 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603566's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,679 | Wei Hu | www.pulike.com.cn |
Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company was founded in 1995 and is headquartered in Luoyang, China.
Pulike Biological Engineering, Inc. Fundamentals Summary
| 603566 fundamental statistics | |
|---|---|
| Market cap | CN¥4.23b |
| Earnings (TTM) | CN¥101.68m |
| Revenue (TTM) | CN¥1.09b |
41.6x
P/E Ratio3.9x
P/S RatioIs 603566 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603566 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.09b |
| Cost of Revenue | CN¥413.20m |
| Gross Profit | CN¥672.69m |
| Other Expenses | CN¥571.01m |
| Earnings | CN¥101.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 25, 2025
| Earnings per share (EPS) | 0.30 |
| Gross Margin | 61.95% |
| Net Profit Margin | 9.36% |
| Debt/Equity Ratio | 0% |
How did 603566 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 05:04 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pulike Biological Engineering, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jia Chen | Changjiang Securities Co. LTD. |
| Bo Chen | Chasing Securities |
| Xie Zhiyou | China Galaxy Securities Co., Ltd. |